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To the Editor: 
 
Since the 1990ies, the application of tandem mass spectrometry in population neonatal 
bloodspot screening (NBS) programs has improved the prognosis for many patients with 
treatable inherited metabolic diseases. However, clinical awareness amongst pediatricians and 
neonatologists remains important as ever, since severe neonatal clinical presentations can 
occur before population NBS test results become available.
1
 In this issue of Genetics in 
Medicine, the authors of “Morbidity and mortality among exclusively breastfed neonates with 
medium-chain acyl-CoA dehydrogenase deficiency” highlight the importance of the feeding 
regimens for these neonates at risk.
2
 In their paper, Ahrens-Nicklas et al. retrospectively 
studied a cohort of patients with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency 
(MIM #201450) and report that 23.9% (11/46) of the infants were symptomatic before the 
return of the NBS results, of which four died or suffered from a cardiac arrest. All 
symptomatic neonates had been exclusively breastfed. This is important as it may not be 
known to pediatricians and neonatologists that a substantial percentage of newborns with 
MCAD deficiency are symptomatic during the first days of life. In addition, the authors 
mention six neonates with an older sibling known to have MCAD deficiency, who were 
carefully monitored and of which five received supplemental feeding. None of the six 
carefully monitored neonates suffered from metabolic decompensation. 
After the pilot NBS study in our region of the Netherlands in 2003-2005, we have 
developed a perinatal protocol for health care providers and families to monitor neonates at 
increased risk of MCAD deficiency (Table 1). Parents are instructed to contact the metabolic 
team around the end of the first trimester of a new pregnancy. Thereafter, an information 
letter is shared with the parents and the health care providers (including general practitioner 
midwife, obstetrician and pediatrician, when applicable), which includes the perinatal 
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monitoring protocol and contact details of our pediatric metabolic team for 24/7 consultation. 
Depending on the clinical situation, parents either call us within 24 hours after birth or 
transfer our contact details to the involved health care providers. In agreement with the report 
by Ahrens-Nicklas et al.
2
, in our protocol we emphasize the importance of a guaranteed 
minimal intake in milliliters during the first days. However, to date we have not 
communicated any preference between either formula milk or mother’s milk obtained after 
breast pumping. 
 In the Dutch population NBS program in 2013, only 62% of the positive neonates 
have been referred to a metabolic physician before day 8. Therefore, our protocol has 
included analysis of dried bloodspot acylcarnitines already before NBS test results can 
become available. Usually, the dried blood spots are delivered to our center by family 
members at the second day of life and the results of acylcarnitine analysis are reported the 
same day. Although not formally studied, parents reported to us that the protocol importantly 
reduces the stress about the diagnosis and feeding regimen while awaiting the results of the 
national NBS program. Table 2 presents acylcarnitine concentrations in umbilical cord blood 
and the first days of life in two (c.985A>G ACADM homozygote) MCAD deficient neonates 
from families, in which the index patients were identified earlier by the NBS program. These 
results illustrate that cord blood acylcarnitines may offer a fast biochemical diagnosis in these 
newborns. In our (still relatively limited) experience, neonates in whom MCAD deficiency 
was excluded have normal (ratios of) acylcarnitines in umbilical cord blood.  
Walter et al. studied the overall feasibility of acylcarnitine and amino acid analysis by 
tandem mass spectrometry in umbilical cord blood for identification of inherited metabolic 
diseases.
3
 These authors mentioned several limitations of umbilical cord blood metabolite 
screening. First, depending on the nature of the metabolic defect and the role of enteral 
feeding and fasting, by far not all inherited metabolic diseases can be detected.
3
 However, the 
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feasibility of more rapid identification also depends on the nature of the disorder. Walter et al. 
used only cut-off values for acylcarnitine concentrations, additional use of their molar ratios 
might increase the detection rate of some disorders.
3
 Despite reports on age related variations 
in acylcarnitine concentrations comparing umbilical cord blood samples with NBS samples
4,5
, 
dried cord blood spot acylcarnitine reference values for concentrations including their molar 
ratios are not available yet. Second, theoretically umbilical blood acylcarnitines can be 
influenced by the maternal (nutritional and/or disease) status.
3
 This problem can be 
circumvented by sequential acylcarnitine (ratio) analysis. Therefore, acylcarnitine 
concentrations in umbilical cord blood may provide an early indication in addition to the 
regular NBS program. 
The abnormal umbilical cord blood acylcarnitine profiles in MCAD deficient neonates 
may indicate the importance of mitochondrial fatty acid oxidation prenatally and during the 
perinatal transition. This period is characterized by important changes in cardiac energy 
metabolism (i.e. from predominantly carbohydrate driven towards mitochondrial fatty acid 
driven), besides the changes from a passive, fetal towards an active, neonatal glucose 
homeostasis and thermoregulation. 
To summarize, a substantial percentage of newborns with MCAD are symptomatic 
during the first days of life. Therefore, a perinatal protocol is important and reduces the risk of 
early clinical ascertainment. Analysis of umbilical dried blood spot acylcarnitines (and their 
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Legends to tables: 
 
Table 1. Perinatal protocol for neonates at risk of MCAD deficiency pending population 
NBS results. Legend: day 0 is defined as the day of birth. 
 
Table 2. Dried bloodspot acylcarnitine profiles in two neonates with MCAD deficiency. 
Legend: day 0 is defined as the day of birth. 
